Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder

Transplantation

Volumn 86, Issue 2, 2008, Pages 215-222

  Swinnen, Lode J ^a   Leblanc, Michael ^b   Grogan, Thomas M ^c   Gordon, Leo I ^d   Stiff, Patrick J ^e   Miller, Alan M ^f   Kasamon, Yvette ^a   Miller, Thomas P ^c   Fisher, Richard I ^g  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Immunosuppressive reduction; Lymphoma; PTLD; S9239

Indexed keywords

ACICLOVIR; ALPHA2B INTERFERON; AZATHIOPRINE; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; VINCRISTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CARDIAC GRAFT REJECTION; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART MUSCLE BIOPSY; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INDUCED HYPOTENSION; INFECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LIVER TOXICITY; LOADING DRUG DOSE; LUNG TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE DRUG DOSE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; REPEATED DRUG DOSE; SEIZURE; SIDE EFFECT; SOMNOLENCE; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEAKNESS; HEART TRANSPLANTATION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METHODOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION;

ACYCLOVIR; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2B; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REMISSION INDUCTION; TACROLIMUS;

EID: 49249097559     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181761659     Document Type: Article

References (25)

1. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 1(11 suppl): 113.
2. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of ritux-imab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053.
3. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant2005; 5: 2901.
4. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for post-cardiac transplant lymphoproliferation. Blood 1995; 86: 3333.
5. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913.
6. Morrison VA, Dunn DL, Manivel JC, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14.
7. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lym-phoproliferative disorders with interferon alfa and intravenous gamma globulin [letter]. N Engl J Med 1988; 318: 1334.
8. Liebowitz D, Anastasi J, Hagos F, et al. Post-transplant lymphopro-liferative disorders (PTLD): Clinicopathologic characterization and response to immunomodulatory therapy with interferon-αlpha [Abstract]. Ann Oncol 1996; 7: 28.
9. Davis CL, Wood BL, Sabath DE, et al. Interferon-αlpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation1998; 66: 1770.
10. Choquet S, Leblond V, Jager U, et al. Efficacy of CHOP regimen as first line therapy in posttransplantation lymphoproliferative disorders (PTLD) [Abstract 3897]. Blood 2003; 102: 49b.
11. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders.Curr Probl Surg 1988; 25: 367.
12. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphopro-liferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877; discussion 886.
13. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961.
14. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphopro-liferative disorders. J Clin Oncol 2001; 19: 772.
15. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphopro-liferative disorders. J Clin Oncol 2001; 19: 772.
16. Ghobrial IM, Habermann TM, Maurer MJ, et al. Proposed prognostic model for survival in solid organ transplant recipients with post transplant lymphoproliferative disorders (PTLD) [Abstract 1423]. Blood 2003; 102: 392a.
17. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosup-pression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation2001; 71: 1076.
18. Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid or- gan transplant patients: Are they two different diseases? Transplantation2005; 79: 244.
19. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosup-pression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation2001; 71: 1076.
20. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphopro-liferative disorders. J Clin Oncol 2001; 19: 772.
21. Davis CL, Wood BL, Sabath DE, et al. Interferon-αlpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation1998; 66: 1770.
22. Milpied N, Antoine C, Garnier JL, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in B post-transplant lymphoproliferative disorders (B PTLDs): A retrospective analysis of 32 patients [Abstract]. Ann Oncol 1999; 10: 5.
23. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of ritux-imab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053.
24. FischerA,Blanche S,LeBidois J,et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451.
25. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998; 92: 3137.